Digilab Acquires BioVisioN to Develop Disease-Management Products
Digilab announced this week that it has acquired peptide-profiler BioVisioN.
"We plan to integrate proprietary Digilab tools into research processes and ultimately disease management systems," said Digilab President David Giddings in a statement.
Financial details were not released.
BioVisioN patented the Peptidomics technology and Differential Peptide Display software for peptide biomarker discovery. It is based in Hannover, Germany.